174 related articles for article (PubMed ID: 32942818)
1. [A single-center retrospective analysis of 85 children and adolescents with limited-stage Hodgkin lymphoma].
Wu B; Wang J; Zhu J; Zhen ZZ; Lu SY; Sun FF; Huang JT; Sun XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):649-654. PubMed ID: 32942818
[No Abstract] [Full Text] [Related]
2. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
3. The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD.
Ingley KM; Nadel HR; Potts JE; Wilson DC; Eftekhari A; Deyell RJ
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e87-e93. PubMed ID: 31259825
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
5. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.
Gunther JR; Fanale MA; Reddy JP; Akhtari M; Smith GL; Pinnix CC; Milgrom SA; Yehia ZA; Allen PK; Osborne EM; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):110-8. PubMed ID: 27325479
[TBL] [Abstract][Full Text] [Related]
7. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
Hay AE; Klimm B; Chen BE; Goergen H; Shepherd LE; Fuchs M; Gospodarowicz MK; Borchmann P; Connors JM; Markova J; Crump M; Lohri A; Winter JN; Dörken B; Pearcey RG; Diehl V; Horning SJ; Eich HT; Engert A; Meyer RM;
Ann Oncol; 2013 Dec; 24(12):3065-9. PubMed ID: 24121121
[TBL] [Abstract][Full Text] [Related]
8. ABVD-Based Therapy for Hodgkin Lymphoma in Children and Adolescents: Lessons Learnt in a Tertiary Care Oncology Center in a Developing Country.
Jain S; Kapoor G; Bajpai R
Pediatr Blood Cancer; 2016 Jun; 63(6):1024-30. PubMed ID: 26855007
[TBL] [Abstract][Full Text] [Related]
9. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
10. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.
Nachman JB; Sposto R; Herzog P; Gilchrist GS; Wolden SL; Thomson J; Kadin ME; Pattengale P; Davis PC; Hutchinson RJ; White K;
J Clin Oncol; 2002 Sep; 20(18):3765-71. PubMed ID: 12228196
[TBL] [Abstract][Full Text] [Related]
12. Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India.
Parambil BC; Narula G; Prasad M; Shah S; Shet T; Shridhar E; Khanna N; Laskar S; Gujral S; Sankaran H; Banavali S
Pediatr Blood Cancer; 2020 Feb; 67(2):e28058. PubMed ID: 31724304
[TBL] [Abstract][Full Text] [Related]
13. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H; ;
Haematologica; 2007 Feb; 92(2):191-8. PubMed ID: 17296568
[TBL] [Abstract][Full Text] [Related]
14. ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma.
Marr KC; Connors JM; Savage KJ; Goddard KJ; Deyell RJ
Ann Oncol; 2017 Apr; 28(4):849-854. PubMed ID: 28327925
[TBL] [Abstract][Full Text] [Related]
15. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
[TBL] [Abstract][Full Text] [Related]
17. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
[TBL] [Abstract][Full Text] [Related]
18. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
19. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
20. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy.
Phan J; Mazloom A; Abboud M; Salehpour M; Reed V; Zreik T; Shihadeh F; Fisher C; Wogan C; Dabaja B
Am J Clin Oncol; 2011 Oct; 34(5):499-505. PubMed ID: 21537149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]